IUPAC/Chemical Name
(S)-2-amino-3-(4-hydroxyphenyl)-N-((R)-1-(2-(isopentylamino)acetamido)-1-oxopropan-2-yl)propanamide
InChi Key
QOGVSHVPIMZZRN-CJNGLKHVSA-N
InChi Code
InChI=1S/C19H30N4O4/c1-12(2)8-9-21-11-17(25)23-18(26)13(3)22-19(27)16(20)10-14-4-6-15(24)7-5-14/h4-7,12-13,16,21,24H,8-11,20H2,1-3H3,(H,22,27)(H,23,25,26)/t13-,16+/m1/s1
SMILES Code
CC(CCNCC(NC([C@H](NC([C@H](Cc1ccc(O)cc1)N)=O)C)=O)=O)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
378.47
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Tive LA, Pick CG, Paul D, Roques BP, Gacel GA, Pasternak GW. Analgesic potency of TRIMU-5: a mixed mu 2 opioid receptor agonist/mu 1 opioid receptor antagonist. Eur J Pharmacol. 1992 Jun 5;216(2):249-55. doi: 10.1016/0014-2999(92)90367-d. PMID: 1327812.
2: Eisenberg RM. TRIMU-5, a mu 2-opioid receptor agonist, stimulates the hypothalamo-pituitary-adrenal axis. Pharmacol Biochem Behav. 1994 Apr;47(4):943-6. doi: 10.1016/0091-3057(94)90300-x. PMID: 8029266.
3: Pick CG, Roques B, Gacel G, Pasternak GW. Supraspinal mu 2-opioid receptors mediate spinal/supraspinal morphine synergy. Eur J Pharmacol. 1992 Sep 22;220(2-3):275-7. doi: 10.1016/0014-2999(92)90761-r. PMID: 1330618.
4: Gacel G, Zajac JM, Delay-Goyet P, Daugé V, Roques BP. Investigation of the structural parameters involved in the mu and delta opioid receptor discrimination of linear enkephalin-related peptides. J Med Chem. 1988 Feb;31(2):374-83. doi: 10.1021/jm00397a019. PMID: 2828622.
5: Dauge V, Petit F, Rossignol P, Roques BP. Use of mu and delta opioid peptides of various selectivity gives further evidence of specific involvement of mu opioid receptors in supraspinal analgesia (tail-flick test). Eur J Pharmacol. 1987 Sep 11;141(2):171-8. doi: 10.1016/0014-2999(87)90260-3. PMID: 2824213.
6: Chneiweiss H, Glowinski J, Premont J. Mu and delta opiate receptors coupled negatively to adenylate cyclase on embryonic neurons from the mouse striatum in primary cultures. J Neurosci. 1988 Sep;8(9):3376-82. doi: 10.1523/JNEUROSCI.08-09-03376.1988. PMID: 2845021; PMCID: PMC6569459.
7: Roques BP. Pharmacologie des différentes classes de récepteurs opioïdes cérébraux [The pharmacology of various classes of cerebral opioid receptors]. Ann Endocrinol (Paris). 1986;47(2):88-96. French. PMID: 3026230.
